PPARG and type 2 diabetes mellitus: Among the many synthetic ligands, TZDs are PPARγ-selective agonists with high affinity, including troglitazone, rosiglitazone, and PIO, which are significantly effective in the treatment of type 2 diabetes and cardiovascular complications [19].